Original Article
  

Evaluation of Salivary sIgA Levels in Hospitalized COVID-19 Patients with COVID-19 Disease Severity: A Cross-sectional Study

Abstract

Since late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) pandemic has dramatically affected public health worldwide. Although systemic antibodies like Immunoglobulin G (IgG) and Immunoglobulin M (IgM)have been widely studied in Coronavirus disease 2019 (COVID-19), the role of Immunoglobulin A (IgA) in mucosal immunity remains less understood. This study evaluated whether salivary IgA levels could serve as prognostic markers for disease severity, progression, and outcomes in hospitalized patients with COVID-19.
In this cross-sectional study, 61 hospitalized patients with COVID-19 were enrolled. After obtaining informed consent, saliva samples were collected at admission to measure IgA levels using an ELISA-based assay (Dlametra kit). Comprehensive clinical and laboratory data, including chest CT results, oxygen saturation, inflammatory markers, and clinical outcomes, were also recorded. Statistical tests were used to examine the association between salivary IgA levels and disease severity, progression, and outcomes.
We enrolled 61 hospitalized patients with COVID-19 (30 females, 31 males; mean age: 56.20 ± 17.45 years; mean admission oxygen saturation: 89.98 ± 5.77%). At admission, 39.3% of patients reported dyspnea, and 40% demonstrated severe lung involvement on chest CT scans. The mean salivary IgA level was 1729.69 ± 391.35 mg/dL. No significant associations were found between salivary IgA levels and COVID-19 severity, disease progression, or clinical outcomes, including mortality.
Our findings show that salivary IgA levels did not significantly correlate with COVID-19 severity, disease progression, or clinical outcomes in hospitalized patients. Therefore, salivary IgA alone cannot be recommended as a prognostic biomarker for COVID-19. Further research is needed to identify more reliable immunological indicators for predicting COVID-19 severity and outcomes.

1. Guarner J. Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19. Am J Clin Pathol. 2020;153(4):420–1.
2. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report – 1. 21 Jan 2020.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
5. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. N Engl J Med. 2020;383(25):2451–60.
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA. 2020;323(18):1824–36.
7. World Health Organization. WHO coronavirus (COVID-19) dashboard. Accessed January 5, 2021.
8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA. 2020;324(8):782–93.
9. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19). Ann Intern Med. 2020;172(9):577–82.
10. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–5.
11. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32–40.
12. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. IgA responses to SARS-CoV-2: holding the fort at the mucosal frontier. Nat Rev Immunol. 2020;20(7):383–4.
13. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577):eabd2223.
14. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.e8.
15. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv. 2020;2020.08.01.20166553.
16. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. J Clin Microbiol. 2020;59(1):e02204-20.
17. Varadhachary A, Chatterjee D, Garza J, Garr R, Foley C, Letkeman A, et al. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. medRxiv. 2020;2020.08.07.20170258.
18. Zervou FN, Angelidi AM, Kreetapirom K, Zervou EK, Giamarellos-Bourboulis EJ, Eliopoulos AG, et al. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol. 2021;93(9):5409–15.
19. Dahlke C, Heidepriem J, Kobbe R, Santer R, Koch T, Fathi A, et al. Distinct early IgA profile may determine the severity of COVID-19 symptoms: an immunological case series. medRxiv. 2020;2020.04.14.20059733.
20. Vâţă A, Ciofu C, Dorobăț CM, Luca V, Manciuc C, Luca A, et al. Clinical significance of early IgA anti-SARS-CoV-2 antibody detection in patients from a Romanian referral COVID-19 hospital. Exp Ther Med. 2022;23(6):1–8.
21. Xue M, Zhang X, Gao Y, Wang W, Guo Q, Li W, et al. Predictive effects of IgA and IgG combination to assess pulmonary exudation progression in COVID-19 patients. J Med Virol. 2021;93(3):1443–8.
22. Rangel-Ramírez VV, García-Chagollán M, Solano-González E, Muñoz-Valle JF, Salgado-Bustamante M, Márquez-López Z, et al. A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: is there a role for IgA in COVID-19 diagnosis or severity? Microbiol Res. 2022;263:127105.
23. Kostinov M, Svitich O, Tarasova V, Shakhov A, Chuchalin A, Dolgikh T, et al. Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms. Drugs Context. 2023;12:2022-10-4.
24. Kostinov M, Svitich O, Tarasova V, Shakhov A, Chuchalin A, Dolgikh T, et al. Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy. Sci Rep. 2024;14(1):11101.
25. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–5.
26. Barzegar-Amini M, Barzegar-Amini E, Shahbazi M, Eslami M, Ghasemi M, Asgarian-Omran H, et al. Comparison of serum total IgA levels in severe and mild COVID-19 patients and control group. J Clin Immunol. 2022;():1–9.
27. Huang Z, Chen H, Xue M, Huang X, Gao Y, Xu J, et al. Characteristics and roles of SARS-CoV-2-specific antibodies in patients with different severities of COVID-19. Clin Exp Immunol. 2020;202(2):210–9.
28. Sinnberg T, Stoehr CG, Koenig W, Meinlschmidt G, Elsner M, Schuster C, et al. IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19. medRxiv. 2021;2021.02.02.21250940.
Files
IssueArticles in Press QRcode
SectionOriginal Article(s)
Keywords
COVID-19 Immunoglobulin A Immunity Mucosal Prognosis Secretory
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Valizadeh Z, Ghaderkhani S, Eshraghi S, Abbasian L, Abdollahi A, Soori T, Roozbahani MM. Evaluation of Salivary sIgA Levels in Hospitalized COVID-19 Patients with COVID-19 Disease Severity: A Cross-sectional Study. Iran J Allergy Asthma Immunol. 2025;:1-8.